Dublin, Ireland, and Columbia, MD, USA, 17 March 2008 - AGI Therapeutics plc
("AGI" or the "Company"), a specialty pharmaceuticals company focused on
gastrointestinal drug products, today announces the completion of the
optimisation phase of development of AGI-010, a modified release formulation of
the proton pump inhibitor drug ("PPI") omeprazole which utilizes AGI's CHRONAB
technology.
